Aperio Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Aperio Group’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$325K	Buy	+2,666	New	+$292K	﹤0.01%	2155

Other funds holding TPTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aperio Group's TPTX Position: Q4 2020 in Review

Aperio Group opened a new position in Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2020: 2,666 shares worth $325K. The stake represents ﹤0.01% of the portfolio and ranks #2155 among its holdings.

193 funds tracked by Wall St. Rank hold TPTX as of Q4 2020.

Aperio Group held 2,666 shares of Turning Point Therapeutics, Inc. Common Stock worth $325K as of Q4 2020.
Turning Point Therapeutics, Inc. Common Stock was a new Aperio Group position in Q4 2020.
Turning Point Therapeutics, Inc. Common Stock made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2155 holding.
193 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.